Diffusion Kurtosis Imaging as a Prognostic Marker in Osteosarcoma Patients with Preoperative Chemotherapy

Table 3

Association of DKI with the OS and PFS of patients with osteosarcoma ().

Variable	OS			PFS
	Overall death/total	Log-rank	aHR (95% CI)	Pro/total	Log-rank	aHR (95% CI)
Tumor response		0.009			0.015
GR	1/13		1.0	3/13		1.0
PR	9/17		9.4 (1.2-75)	12/17		4.2 (1.2-15)
Pre MK		0.49			0.54
≥0.94	4/10		1.0	6/10		1.0
<0.94	6/20		0.6 (0.2-2.3)	9/20		0.6 (0.1-8.8)
Pre MD		0.83			0.63
≥1.32	8/25		1.0	12/25		1.0
<1.32	2/5		1.1 (0.1-18.2)	3/5		1.3 (0.4-4.8)
Post MK		0.03			0.02
≥0.80	5/9		1.0	7/9		1.0
<0.80	5/21		0.3 (0.1-0.9)	8/21		0.3 (0.1-0.8)
Post MD		0.004			0.01
≥1.66	3/18		1.0	6/18		1.0
<1.66	7/12		5.8 (1.5-23.1)	9/12		3.5 (1.2-10.1)
CR MK (%)		0.14			0.17
≥-16.89	5/11		1.0	7/11		1.0
<-16.89	5/19		0.4 (01-1.4)	8/19		0.5 (0.2-1.3)
CR MD (%)		0.001			0.04
≥13.53	2/17		1.0	6/17		1.0
<13.53	8/13		8.6 (1.8-41.8)	9/13		2.9 (1.0-8.2)
Combined effect		0.068			0.052
Group 1	3/16		1.0	5/16		1.0
Group 2	4/7		5.2 (1.1-24.2)	5/7		3.4 (0.9-11.9)
Group 3	3/7		3.0 (0.6-15.0)	5/7		3.6 (1.1-12.6)

GR: good responder; PR: poor responder; pre MK: mean kurtosis before neoadjuvant chemotherapy; pre MD: mean diffusivity before neoadjuvant chemotherapy; post MK: mean kurtosis after neoadjuvant chemotherapy; post MD: mean kurtosis after neoadjuvant chemotherapy; CR MK: change rate in mean kurtosis; CR MD: change rate in mean kurtosis in mean diffusivity; aHR: adjusted for age, sex, location, stage, pathological subtype, and treatment; HR: hazard ratio; CI: confidence interval. . Group 1: patients with and . Group 2: patients with and . Group 3: patients with other parameters. MD is given in .